ACELYRIN, INC. (SLRN)
(Delayed Data from NSDQ)
$4.98 USD
+0.07 (1.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $4.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Price, Consensus and EPS Surprise
SLRN 4.98 +0.07(1.43%)
Will SLRN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for SLRN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SLRN
ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study
ACELYRIN (SLRN) Fails to Meet Goal in HS Study, Stock Down 54%
SLRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SLRN
Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August
UCB gets expanded FDA approval for psoriasis drug Bimzelx
Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch
Acelyrin spikes as late-stage data for lead asset selected for medical event
Acelyrin announces positive results from Phase 3 trial of izokibep